Mike Thompson has been appointed as Chief Executive of the ABPI, effective 1 March 2016.
11 Feb 2016 Posted in News Release By Press Office
Mike is a strategically minded leader who has worked across multiple sectors including pharmaceuticals, food, drinks, toiletries and Government agencies. At the end of 2015, he left GlaxoSmithKline after 20 years with the company, most recently as Senior Vice President of Global Commercial Strategy and Platforms, where he led teams of experts in areas such as multi-channel, payers, market research and analytics. Mike has had experience in working to support colleagues in research and development to bring new medicines to launch.
His experience prior to this includes seven years as the Commercial Strategy Head for Europe and before that, ten years in the UK Operating Company in a variety of senior sales and marketing roles.
Prior to joining Glaxo, Mike worked for Unilever in their food and toiletries divisions, joining as a Commercial Trainee and latterly becoming a Marketing Director in the UK.
ABPI President John Kearney said: "As President, I am looking forward to working with Mike and am convinced that his deep knowledge of our industry, his passion for what we do and his strategic capabilities will be huge assets for the ABPI as we look to build on the progress we have made in recent years. Amidst unrelenting and escalating pressure, our industry is making strong progress, putting patient access to our innovative medicines at the heart of what we do.
"I also wish to recognise and thank the outgoing Acting CEO, Alison Clough, for her outstanding commitment and contribution over the last 12 months ensuring the ABPI remains firmly at the forefront of the UK Life Sciences sector and creating a solid foundation on which Mike can build."
Mike Thompson said: "The pharmaceutical industry has an outstanding track record of delivering real innovation to both the NHS and to patients. Our significant role within life sciences also helps underpin the UK's position as a scientific superpower. Yet current trends show real challenges in sustaining these benefits across the UK today.
"So whilst enormously proud to take up this leadership role, I also take it up with a real commitment to work with all stakeholders to reverse these trends and ensure that everyone can access the multi-faceted benefits which accrue through the impact of this critical, research-based, innovative, industry."
ABPI Press Office
Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying around 90 per cent of all medicines used by the NHS, and are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.